Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „baricitinib“
Suchtreffer
Begriffe & Kennungen
Olumiant · 4.5 · Cytochrome P450 enzymes In clinical pharmacology studies, coadministration of baricitinib with the CYP3A subst
Eintrag öffnenOlumiant · 4.5 · Cytochrome P450 enzymes In clinical pharmacology studies, coadministration of baricitinib with the CYP3A subst
Eintrag öffnenOlumiant · 4.5 · Cytochrome P450 enzymes In vitro, baricitinib is a cytochrome P450 enzyme (CYP)3A4 substrate although less tha
Eintrag öffnenOlumiant · 4.5 · Cytochrome P450 enzymes In vitro, baricitinib is a cytochrome P450 enzyme (CYP)3A4 substrate although less tha
Eintrag öffnenOlumiant · 4.5 · Potential for baricitinib to affect the pharmacokinetics of other medicinal products
Eintrag öffnenOlumiant · 4.5 · Potential for baricitinib to affect the pharmacokinetics of other medicinal products
Eintrag öffnenOlumiant · 4.5 · Potential for other medicinal products to affect the pharmacokinetics of baricitinib
Eintrag öffnenOlumiant · 4.5 · Potential for other medicinal products to affect the pharmacokinetics of baricitinib
Eintrag öffnenOlumiant · 4.5 · Transporters In vitro, baricitinib is a substrate for organic anionic transporter (OAT)3, P-glycoprotein (Pgp)
Eintrag öffnenOlumiant · 4.5 · Transporters In vitro, baricitinib is a substrate for organic anionic transporter (OAT)3, P-glycoprotein (Pgp)
Eintrag öffnenOlumiant · 4.5 · Transporters In vitro, baricitinib is not an inhibitor of OAT1, OAT2, OAT3, organic cationic transporter (OCT)
Eintrag öffnenOlumiant · 4.5 · Transporters In vitro, baricitinib is not an inhibitor of OAT1, OAT2, OAT3, organic cationic transporter (OCT)
Eintrag öffnenOlumiant · 4.8 · Creatine phosphokinase (CPK) Baricitinib treatment was associated with dose-dependent increases in CPK. Mean C
Eintrag öffnenOlumiant · 4.8 · Creatine phosphokinase (CPK) Baricitinib treatment was associated with dose-dependent increases in CPK. Mean C
Eintrag öffnenOlumiant · 4.8 · In paediatric patients treated with baricitinib in the placebo-controlled double-blind randomised withdrawal p
Eintrag öffnenOlumiant · 4.8 · In paediatric patients treated with baricitinib in the placebo-controlled double-blind randomised withdrawal p
Eintrag öffnenOlumiant · 4.8 · In patients with rheumatoid arthritis, the combination of baricitinib with potentially hepatotoxic medicinal p
Eintrag öffnenOlumiant · 4.8 · In patients with rheumatoid arthritis, the combination of baricitinib with potentially hepatotoxic medicinal p
Eintrag öffnenOlumiant · 4.8 · The incidence of serious infections with baricitinib was similar to placebo. The incidence of serious infectio
Eintrag öffnenOlumiant · 4.8 · The incidence of serious infections with baricitinib was similar to placebo. The incidence of serious infectio
Eintrag öffnen